Price history
Select outcomes to plot.
Description
Hantavirus vaccine in 2026? tracks whether any human Hantavirus vaccine—targeting HPS or HFRS—receives full FDA approval by December 31, 2026, 11:59 PM ET. Settlement relies on the FDA’s official approvals list or a credible reporting consensus if necessary. The ruling excludes vaccines not intended for humans and any approvals after the deadline.
Event stats
24h volume
Total volume
Liquidity
Markets
1
Market highlights
Top market
24h gainer
24h loser
Highest volume
Top market
24h gainer
24h loser
Highest volume
Related events
Highest temperature in Taipei on May 4?Highest temperature in Seoul on May 4?Highest temperature in London on May 4?Highest temperature in Singapore on May 4?Highest temperature in Hong Kong on May 4?Highest temperature in Paris on May 4?Highest temperature in Madrid on May 4?Highest temperature in Miami on May 4?Highest temperature in Ankara on May 4?Highest temperature in Shanghai on May 4?
Markets
Outcome | Odds | Spread | 24h Change | 24h Volume | Total Volume | Liquidity | |
|---|---|---|---|---|---|---|---|
| Hantavirus vaccine in 2026? | — | — | — | — | — | — |
Rules
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.